COPD Management Plan 2021
• A single dose of pneumococcal vaccine PPV23 should be administered Pulmonary rehabilitation • Patients should be referred if they have exercise limitation due to breathlessness (NICE Quality Standard, 2016). This is usually MRC 3 or greater (or mMRC≥2). • Main contraindications include uncontrolled cardiovascular disease, significant
Download COPD Management Plan 2021
Information
Domain:
Source:
Link to this page:
Documents from same domain
Rufinamide (Inovelon® ) in the treatment of seizures ...
gmmmg.nhs.ukNOT TO BE USED FOR COMMERCIAL OR MARKETING PURPOSES Date of original recommendation: 22nd June 2010 Date Re-reviewed: 21st October 2014 Rufinamide (Inovelon® ) in the treatment of seizures
FreeStyle Libre Flash Glucose Monitoring System.
gmmmg.nhs.ukNOT TO BE USED FOR COMMERCIAL OR MARKETING PURPOSES November 2017 FreeStyle Libre Flash Glucose Monitoring System. The Formulary and Managed Entry Subgroup discussed the above at its
NTS recommendation Brimonidine gel for acne …
gmmmg.nhs.ukNOT TO BE USED FOR COMMERCIAL OR MARKETING PURPOSES 17th June 2014 Brimonidine (Mirvaso® ) gel for the treatment of acne rosacea erythema. The New Therapies Subgroup (NTS) discussed the above drug at a
Tapentadol (Palexia®) prolonged and immediate …
gmmmg.nhs.ukNovember 2015 Tapentadol (Palexia®) prolonged and immediate release tablets for the treatment of acute and chronic severe pain. The New Therapies Subgroup of the Greater Manchester Medicines
Hydrocortisone modified release tablet …
gmmmg.nhs.ukNOT TO BE USED FOR COMMERCIAL OR MARKETING PURPOSES 17th April 2014 Hydrocortisone modified release tablet (Plenadren®) for the treatment of adrenal …
Low Strength Antipsychotic Prescribing in Dementia: A GP ...
gmmmg.nhs.ukGMMMG – championing the appropriate use of medicines across Greater Manchester PAGE | 4 AIM AIM To aid the primary care review of low strength antipsychotic prescribing in dementia patients.
Chapter 4. Central Nervous System - GMMMG
gmmmg.nhs.ukGreater Manchester Joint Formulary Return to contents page V6.6 Page 6 of 32
GMMMG COPD Formulary Inhaler Options September 2018 ...
gmmmg.nhs.ukGMMMG COPD Formulary Inhaler Options – September 2018 Produced by Regional Drug and Therapeutics Centre (RDTC) for the GMMMG. September 2018 BNF 3.1.2 – Antimuscarinic bronchodilators (LAMA) 1st choice Alternatives Tiotropium Aclidinium Glycopyrronium Umeclidinium
Non-pharmacological management for ALL patients
gmmmg.nhs.uk6 Treatment of new COPD patients FEV 1 Spirometry (measuring FEV 1 and FVC) is needed to make the diagnosis of COPD. FEV 1 can be used to measure worsening or improvement in patients.
Cost Comparison Charts - GMMMG
gmmmg.nhs.ukRegional Drug and Therapeutics Centre Cost comparison charts 2 Jul 2019
Related documents
WORLD HEALTH ORGANIZATION Sickle-cell anaemia
apps.who.intdistribution reflects the fact that sickle-cell trait confers a survival advantage against malaria and that ... from infections including malaria and pneumococcal sepsis, and from the anaemia itself. CLINICAL FEATURES ... to develop models of care appropriate to the management of the disease in sub-Saharan Africa. MANAGEMENT
Immunisation against infectious disease
assets.publishing.service.gov.ukinfectious disease Edited by Dr Mary Ramsay BSc MB BS MRCP MSc MFPHM FFPHM Consultant Epidemiologist UK Health Security Agency First published in 2006 as Immunisation against infectious disease by The Stationery Office, and popularly known as the ‘Green Book’, this publication is
Chapter 25 Pneumococcal anuary 2020 25 - GOV.UK
assets.publishing.service.gov.ukcontact. There is a seasonal variation in pneumococcal disease, with peak levels in the winter months. History and epidemiology of the disease Invasive pneumococcal disease is a major cause of morbidity and mortality. In 2005/6, 6,346 cases of invasive pneumococcal disease were confirmed in England and Wales (Ladhani et al, 2018). It ...
Patient Interview Guide 2 - Nova Southeastern University
cfsecure.nova.eduPATIENT INTERVIEW GUIDE Obtain pertinent demographic information (sometimes you already have this information from the chart) May not need to ask all of the information listed, especially if it is a quick interview
Considerations for Use of PCV15 and PCV20 in U.S. Adults
www.cdc.govFeb 25, 2021 · and 67% of invasive pneumococcal disease cases were in adults with underlying conditions. 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%. Invasive pneumococcal disease Pneumococcal pneumonia Study population. Proportion with underlying conditions in adults aged 50–64 years, 2013–2015. High risk (%) At risk (%) Healthy (%) 71% 67%
The national flu immunisation programme 2020/21 - NHS …
www.england.nhs.ukpneumococcal immunisation sets out all eligible groups for vaccination (apart from those aged two and three on 31 August 2020). It includes eligible frontline health and care workers working in residential care and nursing homes, domiciliary care providers and the voluntary managed hospice sector. The DES can be found at:
1 THE HISTORY AND PHYSICAL (H & P) - LSU Health Sciences ...
www.medschool.lsuhsc.edu1. pneumococcal 2. hepatitis B 3. influenza (yearly) C. Adult illnesses give the type of illness, the dates it occurred, whether hospitalization was required (if so, where?), and a very brief summary of the illness (should be limited to one or two phrases if possible) D. Operations